Literature DB >> 29756251

Fixed Low-Dose Hydroxyurea for the Treatment of Adults with Sickle Cell Anemia in Nigeria.

Bamidele O Tayo1, Titilola S Akingbola2, Santosh L Saraf3, Binal N Shah3, Chinedu A Ezekekwu2, Omowunmi Sonubi2, Lewis L Hsu4, Richard S Cooper1, Victor R Gordeuk3.   

Abstract

Entities:  

Keywords:  Hydroxyurea; fixed low dose; sickle cell anemia; sickle cell disease

Year:  2018        PMID： 29756251      PMCID： PMC6235722          DOI： 10.1002/ajh.25143

Source DB:  PubMed          Journal:  Am J Hematol        ISSN： 0361-8609            Impact factor:   10.047


× No keyword cloud information.
  15 in total

1.  Hydroxyurea lowers transcranial Doppler flow velocities in children with sickle cell anaemia in a Nigerian cohort.

Authors:  IkeOluwa Lagunju; Biobele J Brown; Olugbemiro Sodeinde
Journal:  Pediatr Blood Cancer       Date:  2015-04-01       Impact factor: 3.167

2.  Sickle cell anemia in sub-Saharan Africa: advancing the clinical paradigm through partnerships and research.

Authors:  Patrick T McGann; Arielle G Hernandez; Russell E Ware
Journal:  Blood       Date:  2016-11-07       Impact factor: 22.113

3.  Disseminated nontuberculous mycobacterial infections in sickle cell anemia patients.

Authors:  Emily A Thorell; Mukta Sharma; Mary Anne Jackson; Rangaraj Selvarangan; Gerald M Woods
Journal:  J Pediatr Hematol Oncol       Date:  2006-10       Impact factor: 1.289

4.  Sickle cell disease clinical phenotypes in children from South-Western, Nigeria.

Authors:  S A Adegoke; O O Adeodu; A D Adekile
Journal:  Niger J Clin Pract       Date:  2015 Jan-Feb       Impact factor: 0.968

5.  Stroke recurrence in Nigerian children with sickle cell disease treated with hydroxyurea.

Authors:  I A Lagunju; B J Brown; O O Sodeinde
Journal:  Niger Postgrad Med J       Date:  2013-09

6.  Feasibility trial for primary stroke prevention in children with sickle cell anemia in Nigeria (SPIN trial).

Authors:  Najibah A Galadanci; Shehu Umar Abdullahi; Leah D Vance; Abdulkadir Musa Tabari; Shehi Ali; Raymond Belonwu; Auwal Salihu; Aisha Amal Galadanci; Binta Wudil Jibir; Halima Bello-Manga; Kathleen Neville; Fenella J Kirkham; Yu Shyr; Sharon Phillips; Brittany V Covert; Adetola A Kassim; Lori C Jordan; Muktar H Aliyu; Michael R DeBaun
Journal:  Am J Hematol       Date:  2017-06-15       Impact factor: 10.047

7.  Optimizing Hydroxyurea use in children with sickle cell disease: low dose regimen is effective.

Authors:  Sharef Waadallah Sharef; Maya Al-Hajri; Ismail Beshlawi; Aamir Al-Shahrabally; Mohamed Elshinawy; Mathew Zachariah; Surekha Tony Mevada; Wafaa Bashir; Abdulhakim Rawas; Aqeela Taqi; Zakiya Al-Lamki; Yasser Wali
Journal:  Eur J Haematol       Date:  2013-04-20       Impact factor: 2.997

8.  Low dose hydroxyurea is effective in reducing the incidence of painful crisis and frequency of blood transfusion in sickle cell anemia patients from eastern India.

Authors:  Dilip K Patel; Ranjeet S Mashon; Siris Patel; Bhabani S Das; Prasanta Purohit; Subasa C Bishwal
Journal:  Hemoglobin       Date:  2012       Impact factor: 0.849

9.  Novel use Of Hydroxyurea in an African Region with Malaria (NOHARM): a trial for children with sickle cell anemia.

Authors:  Robert O Opoka; Christopher M Ndugwa; Teresa S Latham; Adam Lane; Heather A Hume; Phillip Kasirye; James S Hodges; Russell E Ware; Chandy C John
Journal:  Blood       Date:  2017-10-19       Impact factor: 22.113

10.  Global burden of sickle cell anaemia in children under five, 2010-2050: modelling based on demographics, excess mortality, and interventions.

Authors:  Frédéric B Piel; Simon I Hay; Sunetra Gupta; David J Weatherall; Thomas N Williams
Journal:  PLoS Med       Date:  2013-07-16       Impact factor: 11.069
View more
  6 in total

1.  Hydroxyurea for Children with Sickle Cell Anemia in Sub-Saharan Africa.

Authors:  Léon Tshilolo; George Tomlinson; Thomas N Williams; Brígida Santos; Peter Olupot-Olupot; Adam Lane; Banu Aygun; Susan E Stuber; Teresa S Latham; Patrick T McGann; Russell E Ware
Journal:  N Engl J Med       Date:  2018-12-01       Impact factor: 91.245

2.  KNOWLEDGE, ATTITUDE AND USE OF HYDROXUYREA AMONG ADULT SICKLE CELL DISEASE PATIENTS.

Authors:  O Sonubi; T R Kotila
Journal:  Ann Ib Postgrad Med       Date:  2019-12

3.  "Maximum tolerated dose" vs "fixed low-dose" hydroxyurea for treatment of adults with sickle cell anemia.

Authors:  Titilola S Akingbola; Bamidele O Tayo; Chinedu A Ezekekwu; Omowunmi Sonubi; Xu Zhang; Santosh L Saraf; Robert Molokie; Lewis L Hsu; Jin Han; Richard S Cooper; Victor R Gordeuk
Journal:  Am J Hematol       Date:  2019-02-06       Impact factor: 10.047

4.  Implementation of the therapeutic use of hydroxyurea for sickle cell disease management in resource-constrained settings: a systematic review of adoption, cost and acceptability.

Authors:  Nessa Ryan; Lotanna Dike; Temitope Ojo; Dorice Vieira; Obiageli Nnodu; Joyce Gyamfi; Emmanuel Peprah
Journal:  BMJ Open       Date:  2020-11-09       Impact factor: 2.692

Review 5.  The Worst Things in Life are Free: The Role of Free Heme in Sickle Cell Disease.

Authors:  Oluwabukola T Gbotosho; Maria G Kapetanaki; Gregory J Kato
Journal:  Front Immunol       Date:  2021-01-27       Impact factor: 7.561

Review 6.  Effective use of hydroxyurea for sickle cell anemia in low-resource countries.

Authors:  Alexandra Power-Hays; Russell E Ware
Journal:  Curr Opin Hematol       Date:  2020-05       Impact factor: 3.218
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.